Japanese electrical products manufacturer TWINBIRD Corporation (TOKYO:6897) on Tuesday announced the SC-UF25 Ultra-Low Temperature Portable Freezer, a compact 25-litre unit capable of reaching −86 degrees C, with commercial release scheduled for November 2026.
The product expands the company's portfolio of Free-Piston Stirling Cooler technology, using helium gas as a refrigerant to support ultra-low-temperature storage and transport of research samples.
Designed for laboratories and life-science organisations, the SC-UF25 offers temperature adjustment from −86C to −20C in 1-degree increments, low-vibration operation and compatibility with 100–240 V power supplies. The freezer aims to reduce reliance on dry ice, improving temperature stability and operational efficiency in cold-chain management for regenerative medicine, cell therapy and drug discovery research.
The product incorporates precision components manufactured in Japan's Tsubame-Sanjo region and is designed for use in laboratories with limited installation space.
TWINBIRD will showcase the SC-UF25 at MEDICA 2026 in Düsseldorf, Germany, from 16 to 19 November, highlighting its potential for research and laboratory cold-chain applications.
The company stated that the freezer is intended exclusively for research, laboratory and life-science cold-chain use and is not registered under the EU Medical Device Regulation or intended for clinical or patient-care applications.
Camurus receives Canadian approval for Oczyesa XR for acromegaly
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Glaukos reports positive Phase 4 results for iDose TR with cataract surgery
Medincell partner Teva secures FDA approval for monthly schizophrenia treatment
Alumis reports new Phase 3 data showing sustained skin clearance with envudeucitinib
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
Sophos IRB and ALCMI partner to support lung cancer research
Innovent Biologics achieves primary study endpoint for inactive thyroid eye disease antibody
argenx reports positive Phase 2 results for FB102 in coeliac disease
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
WuXi AppTec awarded EcoVadis gold medal for third year
Suzhou Ribo Life Science submits Phase I Clinical Trial Application for RBD3133 in EU